Peter J. Neumann

发表

Up Dat e: R esearch R eport Using Decision Analysis To Better Evaluate Pediatric Clinical Guidelines Decision analysis explicitly quantifies an intervention's potential risks, benefits, and costs and is useful where clinical trials are infeasible.

Joshua T. Cohen, Joshua T. Cohen, Peter J. Neumann, 2008 .

PMU14 THE USE OF PERSPECTIVE AND COSTING APPROACHES IN COST-EFFECTIVENESS ANALYSIS

Joshua T. Cohen, Peter J. Neumann, David D. Kim, 2020 .

Do First-In-Class Drugs Offer Larger Incremental Health Gains Than Next-In-Class Drugs?

Peter J. Neumann, James D. Chambers, Teja Thorat, 2016 .

A systematic review of the network meta-analysis literature

Peter J. Neumann, James D. Chambers, Junhee Pyo, 2013 .

Using Cost-Effectiveness Analysis in Health and Medicine

Peter J. Neumann, Murray Krahn, Louise B. Russell, 2016 .

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.

Peter J. Neumann, Michael Drummond, Sean Tunis, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time.

Peter J. Neumann, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

CN3 ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCERTHERAPIES

Eric Nadler, Peter J. Neumann, B. Eckert, 2005 .

Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.

Joshua T. Cohen, Peter J. Neumann, Anirban Basu, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PMU14 The IMPACT of Social and NOVEL Elements on Cost-Effectiveness Analysis: Two Case Studies

Joshua T. Cohen, Peter J. Neumann, Natalia Olchanski, 2021, Value in Health.

Measuring the Value of Prescription Drugs.

Joshua T. Cohen, Peter J. Neumann, P. Neumann, 2015, The New England journal of medicine.

Medicare and medical technology--the growing demand for relevant outcomes.

Peter J. Neumann, Sean Tunis, P. Neumann, 2010, The New England journal of medicine.

30 Years of Pharmaceutical Cost-Utility Analyses

Joshua T. Cohen, Peter J. Neumann, P. Neumann, 2012, PharmacoEconomics.

Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?

Dan Greenberg, Dimitrios Mitsouras, Peter J. Neumann, 2010, The International Journal of Cardiovascular Imaging.

To Your Health: How to Understand What Research Tells Us About Risk

Peter J. Neumann, P. Neumann, 2005 .

Using cost-effectiveness analysis to improve health care: opportunities and barriers.

Peter J. Neumann, P. Neumann, 2004 .

Evaluating HTA principles

Uwe Siebert, Bryan R. Luce, Peter J. Neumann, 2010, International Journal of Technology Assessment in Health Care.

Long-term persistence in use of statin therapy in elderly patients.

Peter J. Neumann, Milton C. Weinstein, Robert J. Glynn, 2002, JAMA.